Neurocrine Biosciences, Inc. (NBIX) fair value analysis

Nasdaq · Updated 2026-09-07

Neurocrine Biosciences, Inc. is a biopharmaceutical company that develops and commercializes medications for neurological, endocrine, and psychiatric disorders. The company operates primarily in the United States and markets its products globally.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, NBIX is trading at more than a 25% discount to estimated fair value.

NBIX currently ranks #18 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $166.23
Sector: Healthcare
12-month range: $131.78–$167.77

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C+
Leverage: Low
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for NBIX

Our model validated 17 trailing price-to-earnings windows for NBIX, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $131.78–$167.77.
The 14-day relative strength index sits at a neutral 44.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for NBIX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent NBIX news

TickrTrends' derived news-sentiment signal for NBIX is currently leaning positive, computed from recent coverage.

NBIX Maintained by Citigroup -- Price Target Raised to $253 (gurufocus.com, 2026-09-03)
TickrTrends take: Citigroup's raised price target to $253 for NBIX reflects analyst confidence in the company's prospects within the Healthcare sector. Given TickrTrends' current assessment that NBIX is undervalued, this analyst action may support the case for a gap between current market pricing and the firm's estimated fair value. Valuation-focused readers should monitor whether this maintained rating from a major institution influences market perception of NBIX's true worth relative to its fundamentals.
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition (manilatimes.net, 2026-08-26)
TickrTrends take: Neurocrine Biosciences' advancement of NBI-1117567 into Phase 2 testing represents progress in its Alzheimer's pipeline, which may eventually contribute to revenue diversification within the Healthcare sector. Given TickrTrends' current undervalued assessment of NBIX, investors monitoring the stock should track clinical development milestones and any updates on this program's efficacy and safety data, as successful trial progression could influence the company's long-term value proposition. The regulatory acceptance signals that the compound has met initial FDA requirements, though typical drug development timelines mean meaningful commercial impact remains years away.
Neurocrine Biosciences Stock: 'House Full Of Options' (NASDAQ:NBIX) (seekingalpha.com, 2026-08-22)
TickrTrends take: Neurocrine Biosciences operates in the Healthcare sector where multiple clinical and commercial pathways can significantly impact valuation outcomes. TickrTrends currently assesses NBIX as undervalued, suggesting the market may not be fully pricing in the value of its pipeline and existing product portfolio. Investors focused on valuation should monitor clinical trial progression and commercial execution across the company's various programs, as successful advancement could narrow any gap between current market price and intrinsic value.

What people are saying

Follow the NBIX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — NBIX in the Healthcare sector has moved from a mixed trend state to an uptrend in its 50/200-day trend indicator this week. The stock maintains an undervalued valuation verdict according to TickrTrends' derived indicators.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is NBIX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), NBIX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is NBIX's TickrTrends verdict?

NBIX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does NBIX compare to other Healthcare stocks?

NBIX ranks #18 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is NBIX overbought or oversold?

NBIX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

NBIX vs AMPH · NBIX vs COO · NBIX vs DXCM · NBIX vs HALO · NBIX vs HQY